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An induced pluripotent stem cell (iPSC) line was generated from a 36-year-old patient with sporadic Parkinson's
disease (PD). Skin broblasts were reprogrammed using the non-integrating Sendai virus technology to deliverfi
OCT3 /4, S OX2, c-MYC a nd KL F4 f actor s. The gene rat e d cel l lin e (CS C-4 3) exh ibits expre ssi on of common
pluripotency markers, differentiation into three germ layers and normal karyotype. This iPSC line canin vitro
be used to study the mechanisms underlying the development of PD.
© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND l icense (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Institution Stem Cell Laboratory for CNS Disease Modeling,





Type of cell line iPSC
Origin Human
Additional origin info Age of patient at onset: 31
Sex of patient: male
Ethnicity: N/A




Sendai virus mediated delivery of OCT3/4, SOX2, c-MYC
and KLF4
Genetic Modi cation No modi cationfi fi
Type of Modi cation No modi cationfi fi
Associated disease Parkinson's disease
Gene/locus N/A
Method of modi cation No modi cationfi fi
Name of transgene or
resistance










Ethical approval Parkinson Institute Biobank (part of the Telethon
Genetic Biobank Network http://biobanknetwork.
telethon.it/): approved by Ethics Committee Milano“
Area C (” http://comitatoeticoareac.ospedaleniguarda.
it/) on the 26/06/2015, Numero Registro dei pareri:
370 062015.–
Reprogramming: 202,100 3211 (delivered by Swedish–
work environment Arbetsmiljöverket).
Resource utility
This iPSC line can be used to explore the development of sporadic
Parkinson's disease in vitro.
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Resource details
Dopaminergic neurons obtained from the differentiation of sporadic
Parkin son's d isease (PD) pat ient de rived - induced plurip otent st em
cells (iPSCs) have been shown to express a pathogenic phenotype, in-
cluding morphological alterations and accumulation of autophagic vac-
   uoles (Sánchez-Danés et al., 2012). Here we report the generation of an
induced pluripotent stem cell line (CSC-43) from a patient with early-
onset PD with no identi ed genetic cause, which can be used to under-fi
stand the molecular basis of this neurodegenerative disease.
To gen erate CS C-43 iPSC lin e, sk in fibroblasts collected by punch skin
biopsy from a 36-year-old PD patient were reprogrammed using a non-
integr atin g Senda i viru s tec h nology . Bri e y, brob lasts were se ededfl fi
(75,000 cells/wel l) on a 12-well plate, two days before transduction.
The CytoTune™-iPS 2.0 Sendai Reprogramming Kit was then used to de-
liver the four reprogramming factors, OCT3/4, SOX2, c-MYC and KLF4. At
day 7 post-transduction, the cells were re-seeded onto mouse embry-
onic broblasts (MEF)-feeder lay er and expanded until colonies pre-fi
sented an embr yonic stem c ell ( ES)-li ke m orphol ogy. At day 28, 12
colonie s we re pi cked and exp an ded as indi vi dual clones for 7 days.
Fig. 1. Characterization of the iPSC line CSC 43J.
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Three clones (CSC-43D, CSC-43I and CSC-43J) were further selected for
expansion and karyotype analysis. All clones were characterized using
   the methods we previously described (Holmqvist et al., 2016). We re-
port, herein the characterization of clone CSC-43J.
The generated clone, CSC-43J, expressed the common nuclear and
cell su rface pluripo tenc y marker s, OCT 4/Nanog and TRA1 -81/S SEA4
( A) and showed alkaline phosphat ase ( ALP) activity (Fig. 1 F i g . 1B).
Flow cytometry analysis showed 99% of the iPSCs positive for SSEA4
( C; non-stained iPSCs are shown in grey). Additional immunocyto-Fig. 1
chemistry analysis revealed elimination of the Sendai virus at passage 8
( D). E depicts a normal male karyogram identi ed in CSC-43JFig. 1 Fig. 1 fi
clone. Emb ryoi d bodies (EB s) gener ated fro m CSC- 43J iPSC pre sent
three-germ layer differentiation capacity as shown by the ex-in vitro
pressi on of alpha -fetopr otein ( AFP), an en doderm al marker, smooth
muscle acti n (SMA), a mesodermal marker , and beta -III tu bul in
(BIIITub), an ectodermal marker (Fig. 1F) . The identity of the gen erated
iPSC li ne wa s con rmed by DNA ngerp rint, showi ng ge netic corre -fi fi
spondence to parental broblasts. Mycoplasma infection was preventedfi
by routine addition of plasmocin in cell culture media, at early passages.
Materials andmethods
Fibroblast culture
Dermal broblasts were collected by punch skin biopsy from a pa-fi
tient diagnosed with PD, after obtaining informed consent. The bro-fi
blasts were m ainta ined in brobl ast growt h med iu m, com posed offi
DMEM media (ThermoFisher Scienti c) with 10% fetal bovine serumfi
and 1 % Penicillin -Streptomycin a nd pas saged with 0.05% try psin.
iPSC generation and expansion
For reprogramming, 75,000 cells were seeded on a 12-well plate and
maintained in broblast growth medium. Two days after (day 0), thefi
cells were transduced using the three vector preparations (MOI = 5,
5, 3) inclu ded in the Cy toTune -iPS 2. 0 Senda i Reprog ramm ing Kit™
(Ther m oFish er Sc ienti c). On the f ollow in g da y and on every otherfi
day, the medium was replaced with fresh broblast growth medium.fi
At day 7, the cells were re-seeded onto irradiated mouse embryonic -fi
broblasts (MEFs) feeder cells with broblast growth medium. On thefi
day after and until colony picking, the cells were cultured in WiCell me-
dium composed of advanced DMEM/F12 (ThermoFisher Scientific), 20%
Knock-Out Serum Replacement (v/v, ThermoFisher Scienti c), 2 mMfi L-
gluta mine (Thermo Fisher Sc ie nti c), 1% non-essenti al amino acidsfi
(NEAA, v/v, Millipore) and 0.1 mM -mercaptoethanol, supplemented
with 20 ng/ml FGF2 (Th ermoFisher Scie nti c). On day 28, individu alfi
colonie s were picked and re -seed ed on a 24-well plate contai ning
fresh MEFs. One week after, three clones were selected and further ex-
pande d on 6-well plate s. The c ells were passag ed once a week and
seeded on the appropriate cell culture surface for characterization as-
 says at the indicated passage numbers (Table 1).
Immunocytochemistry
The iPSCs cultures were xed with 4% paraformaldehyde for 15 minfi
at room temperature (RT) , p ermeabilized and bloc ked for 1 h at RT with
PBS containing 10% donkey serum and 0.1% TritonX-100 (Sigma) and
incubated overnight at + 4 °C with the primary antibodies (Table 2) d i-
luted in the blocking buffer. The secondary antibodies were thereafter
added for 1 h at RT in the dark, followed by nucle i counterstain with
DAPI (1:10,000 (Life Technologies)) and image acquisition on inverted
epifluorescence microscope LRI - Olympus IX-73. Scale bars are 200 m.
Alkaline phosphatase activity
Alkaline phosphatase staining was performed using Alkaline Phos-
phatase Staining Kit (Stemgent, MA).
In vitro differentiation by embryoid body (EB) formation
Human iPSC were grown for 2 weeks as embryoid bodies (EBs) in
low-atta chment 2 4-well plate s (Corni ng) in WiC ell mediu m supple -
mented with 20 ng/ml FGF2. The EBs were then seeded on a 0.1% gela-
tin-coated 96-well plate (Greiner Bio-One) in DMEM media containing
10% fetal bovine serum and 1% Penicillin-Streptomycin for subsequent
spontaneous differentiation, with media changes every 2 3 days. After–
2 weeks, the cells were xed and stained for three germ-layer markersfi
 as described in Table 2.
Karyotype analysis
The G-banding analysis was performed at 300–400 band resolution
in aver a ge aft er 11 pa ssage s, at the D epart ment of Clinica l Genet ics
and Pathology in Lund.
DNA fingerprinting
Genomic DNA from broblasts and hiPSCs was extracted using con-fi
ventional lysis buffer composed of 100 mM Tris (pH 8.0), 200 mM NaCl,
5 mM EDTA and 0.2% SDS in distilled autoclaved water supplemented
Table 1
Characterization and validation.
Classi cation Test Result Datafi
Morphology Photography Visual record of the line: Normal Not shown but available
with the author
Phenotype Immunocytochemisty Positive staining for pluripotency markers: OCT4, NANOG, TRA1-81 and SSEA4 panel AFig. 1
Alkaline phosphatase
activity
Visible activity panel BFig. 1
Flow cytometry 99.7% SSEA4 panel CFig. 1
Genotype Karyotype (G-banding)
and resolution
46,XY (300 400 bands resolution in average) panel E– Fig. 1






Mycoplasma Mycoplasma testing by RT-PCR. Negative. Not shown but available
with author
Differentiation potential Embryoid body formation Staining of smooth muscle actin, beta-III-tubulin and alpha-fetoprotein after
spontaneous differentiation of embryoid bodies
Fig. 1 panel F
Donor screening
(optional)





Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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with 1.5 mg/ml Proteinase K. Fingerprinting analyses were outsourced
to the IdentiCell STR pro ling service (Department of Molecular Medi-fi
cine, Aarhus University Hospital, Skejby, Denmark).
Mycoplasma detection
Absence of mycoplasma contamination was con rmed by the real-fi
time PCR method at GATC Biotech AG (European Genome and Diagnos-
tics Centre, Konstanz, Germany).
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Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Mouse anti-Oct4 1:200 Millipore Cat# MAB4401, RRID:AB_2167852
PE-conjugated mouse anti-human Nanog 1:200 BD Biosciences Cat# 560483, RRID:AB_1645522
Mouse anti- TRA-1-81 1:200 Thermo Fisher Scienti c Cat# 41-1100, RRID:fi AB_2533495
PE-conjugated mouse anti-SSEA4 1:200 Thermo Fisher Scienti c Cat# A14766, RRID:fi AB_2534281
Sendai Chicken anti-Sendai virus 1:1000 Abcam Cat# ab33988, RRID:AB_777877
Differentiation Markers Mouse anti-AFP 1:200 Sigma-Aldrich Cat# A8452, RRID:AB_258392
Mouse anti-SMA 1:200 Sigma-Aldrich Cat# A2547, RRID:AB_476701
Mouse anti-BIII tubulin 1:200 Sigma-Aldrich Cat# T8660, RRID:AB_477590
Secondary antibodies Donkey anti-mouse Alexa Fluor® 488 1:400 Molecular Probes Cat# A-21202, RRID:AB_141607
Donkey anti-chicken Alexa Fluor® 488 1:400 Jackson ImmunoResearch Labs Cat# 703-545-155, RRID:AB_2340375
Donkey anti-mouse Alexa Fluor® 555 1:400 Thermo Fisher Scienti c Cat# A-31570, RRID:fi AB_2536180
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